NCT04468646View on ClinicalTrials.gov

To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

July 15, 2020

Study Completion Date

August 30, 2020

Conditions
Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus
Interventions
DRUG

NK-1R antagonist

NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days

Trial Locations (1)

53720

RECRUITING

Bahria International Hospital, Lahore

Sponsors
All Listed Sponsors
collaborator

University of Lahore

OTHER

collaborator

Bahria International Hospital

UNKNOWN

lead

Prof. Dr. Fridoon Jawad Ahmad

OTHER